ROLE OF MODERN TECHNOLOGY FOR TREATMENT OF HCV

U Mushtaq; S Mushtaq; M Afzal; Q Ali; A Malik

doi:10.54112/bcsrj.v2020i1.1

Authors

U Mushtaq Institute of Molecular Biology & Biotechnology, University of Lahore, Lahore, Pakistan
S Mushtaq Institute of Molecular Biology & Biotechnology, University of Lahore, Lahore, Pakistan
M Afzal Institute of Molecular Biology & Biotechnology, University of Lahore, Lahore, Pakistan
Q Ali Institute of Biotechnology and Molecular Biology, The University of Lahore, Lahore
A Malik Institute of Molecular Biology & Biotechnology, University of Lahore, Lahore, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2020i1.1

Keywords:

HCV, liver, ribavirin, cirrhosis, drug, cancer, interferon

Abstract

HCV is the main reason of the liver disease and worldwide it is one of the major issues of health due to its development into cirrhosis, failure and cancer of liver. The transference of HCV is mainly through the parental but people who use drug like intravenous are also at greatest threat. The life cycle of HCV is now understood in a more precise way due to extensive studies. Due to more understanding of this virus there is establishment of more effectual antiviral medications and also diagnostic devices. Test of nucleic acids are suggested for the validation of active HCV. Serology tests are suggested for the groups that are at the greatest risk. Earlier for the standard medications of HCV interferon (IFN-a) and ribavirin are used. Later FDA approved a number of drugs such as harvoni, simeprevir and boceprevir etc. for the proper treatment of HCV. Antiviral medications will be utilized to treat the infections of HCV. In the management of certain severe viral infection, therapeutic option has improved in a better way. There is need of follow-up and careful consideration as well as there are many new technologies that have developed for the quantitative measurement of viral genome concentration in the body fluid of patients. Initially this measurement led to important insight in the viral infection pathogenesis as well as these test also revolutionized natural history of HCV. In addition viral load test are pure tool for research, these are used in routine viral diagnosis. Viral load test are used in clinical virology for diagnosis and prognosis of patient’s.

Downloads

Download data is not yet available.

References

Alberti, A., Boccato, S., Vario, A., and Benvegnù, L. (2002). Therapy of acute hepatitis C. Hepatology 36, S195-S200.

Alter, M. J., Kruszon-Moran, D., Nainan, O. V., McQuillan, G. M., Gao, F., Moyer, L. A., Kaslow, R. A., and Margolis, H. S. (1999). The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. New England journal of medicine 341, 556-562.

Association, A. G. (1995). Policy statement on the use of medical practice guidelines by managed care organizations and insurance carriers. Gastroenterology 108, 6.

Bacon, B. R. (2002). Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 36, s179-s184.

Berger, A., and Preiser, W. (2002). Viral genome quantification as a tool for improving patient management: the example of HIV, HBV, HCV and CMV. Journal of Antimicrobial Chemotherapy 49, 713-721.

Berger, A., Preiser, W., and Doerr, H. W. (2001). The role of viral load determination for the management of human immunodeficiency virus, hepatitis B virus and hepatitis C virus infection. Journal of clinical virology 20, 23-30.

Briggs, M. E., Baker, C., Hall, R., Gaziano, J. M., Gagnon, D., Bzowej, N., and Wright, T. L. (2001). Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center. Hepatology 34, 1200-1205.

Butcher, A., Aslam, S., Hemyari, P., Cowen, U., and Heilek, G. (2014). HCV RNA detection in HCV antibody-positive patients with the COBAS® AmpliPrep/COBAS® TaqMan® HCV test, v2. 0 in comparison with FDA-approved nucleic acid tests. Journal of Clinical Virology 60, 336-340.

Conry-Cantilena, C., VanRaden, M., Gibble, J., Melpolder, J., Shakil, A. O., Viladomiu, L., Cheung, L., DiBisceglie, A., Hoofnagle, J., and Shih, J. W. (1996). Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. New England Journal of Medicine 334, 1691-1696.

Control, C. f. D., and Prevention (2001). Guidelines for laboratory test result reporting of human immunodeficiency virus type 1 ribonucleic acid determination. Recommendations from a CDC working group. Centers for Disease Control. MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports 50, 1.

Davis, G. L. (2002). Monitoring of viral levels during therapy of hepatitis C. Hepatology 36, S145-S151.

De Keukeleire, S., Descheemaeker, P., and Reynders, M. (2015). Potential risk of misclassification HCV 2k/1b strains as HCV 2a/2c using VERSANT HCV Genotype 2.0 assay. Diagnostic microbiology and infectious disease 82, 201-202.

Deeks, E. D. (2015). COBAS® AmpliPrep/COBAS® Taqman® HCV Quantitative Test, Version 2.0: An in vitro test for Hepatitis C virus RNA quantification. Molecular diagnosis & therapy 19, 1-7.

Di Bisceglie, A. M. (2000). Natural history of hepatitis C: its impact on clinical management. Hepatology 31, 1014-1018.

Di Bisceglie, A. M., and Hoofnagle, J. H. (2002). Optimal therapy of hepatitis C. Hepatology 36, S121-S127.

Eddy, D. M. (1996). Clinical decision making: From theory to practice: A collection of essays from the Journal of the American Medical Association.

El-Zayadi, A.-R., Attia, M., Barakat, E. M., Badran, H. M., Hamdy, H., El-Tawil, A., El-Nakeeb, A., Selim, O., and Saied, A. (2005). Response of hepatitis C genotype-4 naive patients to 24 weeks of Peg-interferon-α2b/ribavirin or induction-dose interferon-α2b/ribavirin/amantadine: a non-randomized controlled study. American Journal of Gastroenterology 100, 2447-2452.

Fattovich, G., Giustina, G., Degos, F., Tremolada, F., Diodati, G., Almasio, P., Nevens, F., Solinas, A., Mura, D., and Brouwer, J. (1997). Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112, 463-472.

Fattovich, G., Stroffolini, T., Zagni, I., and Donato, F. (2004). Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127, S35-S50.

Feld, J. J., and Hoofnagle, J. H. (2005). Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436, 967-972.

Fried, M. W. (2002). Side effects of therapy of hepatitis C and their management. Hepatology 36, S237-S244.

Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales Jr, F. L., Häussinger, D., Diago, M., Carosi, G., and Dhumeaux, D. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine 347, 975-982.

Gerlach, J. T., Diepolder, H. M., Zachoval, R., Gruener, N. H., Jung, M.-C., Ulsenheimer, A., Schraut, W. W., albrecht Schirren, C., Waechtler, M., and Backmund, M. (2003). Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 125, 80-88.

Gross, P. A., Barrett, T. L., Dellinger, E. P., Krause, P. J., Martone, W. J., McGowan Jr, J. E., Sweet, R. L., and Wenzel, R. P. (1994). Purpose of quality standards for infectious diseases. Clinical infectious diseases 18, 421-421.

Grüner, N., Viazov, S., Korn, K., Knöll, A., Trippler, M., Schlaak, J., Gerken, G., Roggendorf, M., and Ross, R. S. (2015). Performance characteristics of the VERSANT hepatitis C virus RNA 1.0 (kPCR) assay. International Journal of Medical Microbiology 305, 627-635.

Hadziyannis, S. J., Sette, H., Morgan, T. R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H., Bernstein, D., and Rizzetto, M. (2004). Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Annals of internal medicine 140, 346-355.

Hodinka, R. L. (1998). The clinical utility of viral quantitation using molecular methods. Clinical and diagnostic virology 10, 25-47.

Hofer, H., Watkins‐Riedel, T., Janata, O., Penner, E., Holzmann, H., Steindl‐Munda, P., Gangl, A., and Ferenci, P. (2003). Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 37, 60-64.

Hoofnagle, J. H. (2002). Course and outcome of hepatitis C. Hepatology 36, S21-S29.

Hoofnagle, J. H., and Seeff, L. B. (2006). Peginterferon and ribavirin for chronic hepatitis C. New England Journal of Medicine 355, 2444-2451.

Hu, K., and Tong, M. (1998). The long-term clinical outcomes of patients with HCV-related compensated cirrhosis and history of parenteral exposure. Gastroenterology 114, A1258-A1259.

Hu, K. Q., and Tong, M. J. (1999). The long‐term outcomes of patients with compensated hepatitis C virus–related cirrhosis and history of parenteral exposure in the united states. Hepatology 29, 1311-1316.

Kamal, S. M., Ismail, A., Graham, C. S., He, Q., Rasenack, J. W., Peters, T., Tawil, A. A., Fehr, J. J., Khalifa, K. E. S., and Madwar, M. M. (2004). Pegylated interferon α therapy in acute hepatitis C: Relation to hepatitis C virus–specific T cell response kinetics. Hepatology 39, 1721-1731.

Kim, W. R. (2002). The burden of hepatitis C in the United States. Hepatology 36, S30-S34.

Mazzuti, L., Lozzi, M. A., Riva, E., Maida, P., Falasca, F., Antonelli, G., and Turriziani, O. (2016). Evaluation of performances of VERSANT HCV RNA 1.0 assay (kPCR) and Roche COBAS AmpliPrep/COBAS TaqMan HCV test v2. 0 at low level viremia. New Microbiol 39, 224-7.

McQuillan, G. M., Coleman, P. J., Kruszon-Moran, D., Moyer, L. A., Lambert, S. B., and Margolis, H. S. (1999). Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. American journal of public health 89, 14-18.

Panneer, N., Lontok, E., Branson, B. M., Teo, C.-G., Dan, C., Parker, M., Stekler, J. D., DeMaria Jr, A., and Miller, V. (2014). HIV and hepatitis C virus infection in the United States: whom and how to test. Clinical infectious diseases 59, 875-882.

Pas, S., Molenkamp, R., Schinkel, J., Rebers, S., Copra, C., Seven-Deniz, S., Thamke, D., de Knegt, R., Haagmans, B., and Schutten, M. (2013). Performance evaluation of the new Roche cobas AmpliPrep/cobas TaqMan HCV test, version 2.0, for detection and quantification of hepatitis C virus RNA. Journal of clinical microbiology 51, 238-242.

Pawlotsky, J. M. (2002). Use and interpretation of virological tests for hepatitis C. Hepatology 36, s65-s73.

Pawlotsky, J. M., Lonjon, I., Hezode, C., Raynard, B., Darthuy, F., Remire, J., Soussy, C. J., and Dhumeaux, D. (1998). What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? Hepatology 27, 1700-1702.

Preiser, W., Elzinger, B., and Brink, N. S. (2000). Quantitative molecular virology in patient management. Journal of clinical pathology 53, 76-83.

Pyne, M. T., and Hillyard, D. R. (2013). Evaluation of the Roche COBAS AmpliPrep/COBAS TaqMan HCV Test. Diagnostic microbiology and infectious disease 77, 25-30.

Schreiber, G. (1996). The risk of transfusion-transmitted viral infections. The Epidemiology Donor Study. N Engl J Med 334, 1734-1735.

Shah, B. B., and Wong, J. B. (2006). The economics of hepatitis C virus. Clinics in liver disease 10, 717-734.

Woolf, S. H., and Sox, H. C. (1991). The Expert Panel on Preventive Services: continuing the work of the US Preventive Services Task Force. American journal of preventive medicine 7, 326-330